 Transaction adds late-stage orphan pipeline asset and platform in inflammation and fibrosis. Calliditas to acquire 62.7 of Genkyotex for 20.3M in cash at 2.80 per share in an off-market transaction. Following the closing of the control transaction a mandatory simplified cash tender offer on the same terms for the remaining outstanding shares would be launched. Total consideration for 100 of Genkyotex would amount to 32M, not including milestones of up to 55M payable upon regulatory approvals of setanaxib. 